Ono pays $280M upfront for Ionis' antisense oligonucleotide for rare blood cancer

Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense oligonucleotide for a rare type of blood cancer.